American Renal Associates Holdings, Inc. Announces Filing
of Registration Statement for Proposed Initial Public Offering

BEVERLY, MA (August 31, 2015) - American Renal Associates Holdings, Inc. (“ARA”) today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. The number of shares of common stock to be sold and the price range for the proposed offering have not yet been determined. American Renal Associates Holdings, Inc. has applied to list its common stock on the New York Stock Exchange under the ticker symbol “ARA”.

BofA Merrill Lynch, Barclays, Goldman, Sachs & Co., Wells Fargo Securities and SunTrust Robinson Humphrey are acting as joint book-running managers in the proposed offering. Leerink Partners is acting as a co-manager in the proposed offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained, when available, from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com, Barclays Capital Inc., c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, email: Barclaysprospectus@broadridge.com, Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com, Wells Fargo Securities, LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, email: cmclientsupport@wellsfargo.com, or SunTrust Robinson Humphrey, Inc., Attn: Prospectus Department, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, email: strh.prospectus@suntrust.com.  

A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective. The registration statement and all subsequent amendments can be accessed through the SEC’s website at www.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About American Renal Associates:
As of June 30, 2015, American Renal Associates Holdings, Inc. (ARA) operated 181 dialysis clinic locations in 23 states and the District of Columbia, treating over 12,000 patients with end stage renal disease. ARA operates exclusively through a joint venture model, in which we partner with more than 320 local nephrologists to develop, own and operate dialysis clinics.

American Renal Associates Holdings, Inc. Contact:
Darren Lehrich, SVP of Strategy & Investor Relations
Phone: 978-922-3080 x 134
Email: dlehrich@americanrenal.com